GSA Capital Partners LLP Sells 1,627,753 Shares of Lexicon Pharmaceuticals, Inc. $LXRX

GSA Capital Partners LLP lessened its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 57.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,202,906 shares of the biopharmaceutical company’s stock after selling 1,627,753 shares during the quarter. GSA Capital Partners LLP owned about 0.33% of Lexicon Pharmaceuticals worth $1,624,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of America Corp DE grew its stake in Lexicon Pharmaceuticals by 27.4% during the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 29,319 shares in the last quarter. Invesco Ltd. boosted its holdings in Lexicon Pharmaceuticals by 173.5% in the 1st quarter. Invesco Ltd. now owns 285,759 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 181,265 shares during the period. AQR Capital Management LLC bought a new position in Lexicon Pharmaceuticals in the 1st quarter valued at $541,000. Acadian Asset Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the 1st quarter valued at $263,000. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in shares of Lexicon Pharmaceuticals by 77.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 28,594 shares during the period. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Trading Up 0.8%

NASDAQ LXRX opened at $1.32 on Wednesday. The company has a quick ratio of 5.63, a current ratio of 5.64 and a debt-to-equity ratio of 0.47. The stock’s 50-day simple moving average is $1.28 and its two-hundred day simple moving average is $1.30. Lexicon Pharmaceuticals, Inc. has a twelve month low of $0.28 and a twelve month high of $1.83. The company has a market capitalization of $479.78 million, a price-to-earnings ratio of -6.95 and a beta of 0.98.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LXRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average price target of $3.23.

Insider Transactions at Lexicon Pharmaceuticals

In other Lexicon Pharmaceuticals news, Director Invus Global Management, Llc purchased 1,538,462 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were purchased at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the completion of the purchase, the director owned 1,538,462 shares of the company’s stock, valued at $2,000,000.60. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 13.90% of the stock is currently owned by corporate insiders.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.